GI
STOK icon

GAMMA Investing’s Stoke Therapeutics STOK Stock Holding History

GAMMA Investing’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$27.2K Buy
1,047
+164
+19% +$4.95K ﹤0.01% 2758
2026
Q2 		$28.9K Buy
883
+43
+5% +$1.38K ﹤0.01% 2640
2026
Q1 		$27.4K Buy
840
+10
+1% +$328 ﹤0.01% 2550
2025
Q4 		$26.3K Buy
830
+150
+22% +$4.51K ﹤0.01% 2455
2025
Q3 		$16K Buy
680
+41
+6% +$703 ﹤0.01% 2640
2025
Q2 		$7.25K Sell
639
-167
-21% -$1.59K ﹤0.01% 2965
2025
Q1 		$5.36K Buy
806
+530
+192% +$4.94K ﹤0.01% 3060
2024
Q4 		$3.04K Sell
276
-247
-47% -$3.03K ﹤0.01% 3087
2024
Q3 		$6.43K Buy
523
+270
+107% +$3.83K ﹤0.01% 2644
2024
Q2 		$3.42K Buy
253
+136
+116% +$1.84K ﹤0.01% 2705
2024
Q1 		$1.58K Buy
+117
New +$709 ﹤0.01% 2823

Other funds holding STOK

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's STOK Position: Q3 2026 in Review

GAMMA Investing increased its Stoke Therapeutics (STOK) stake by 19% in Q3 2026, buying an estimated $4.95K and bringing the position to 1,047 shares worth $27.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2758.

GAMMA Investing first reported a position in STOK in Q1 2024 and has held it in 11 quarters since. The position peaked at $28.9K in Q2 2026. 3 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • GAMMA Investing held 1,047 shares of Stoke Therapeutics worth $27.2K as of Q3 2026.
  • GAMMA Investing bought 164 Stoke Therapeutics shares in Q3 2026, an estimated $4.95K.
  • Stoke Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2758 holding.
  • GAMMA Investing first reported a position in Stoke Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • GAMMA Investing's Stoke Therapeutics position peaked at $28.9K in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.